<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812450319</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812450319</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Trends, Correlates, and Disease Patterns of Antidepressant Use Among Children and Adolescents in Taiwan</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chien</surname>
<given-names>I-Chia</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0883073812450319">1</xref>
<xref ref-type="aff" rid="aff2-0883073812450319">2</xref>
<xref ref-type="corresp" rid="corresp1-0883073812450319"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hsu</surname>
<given-names>Yuan-Chang</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812450319">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Happy Kuy-Lok</given-names>
</name>
<degrees>MD, MPH, MHS</degrees>
<xref ref-type="aff" rid="aff1-0883073812450319">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Ching-Heng</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-0883073812450319">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheng</surname>
<given-names>Shu-Wen</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0883073812450319">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chou</surname>
<given-names>Yiing-Jenq</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0883073812450319">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chou</surname>
<given-names>Pesus</given-names>
</name>
<degrees>DrPH</degrees>
<xref ref-type="aff" rid="aff2-0883073812450319">2</xref>
<xref ref-type="aff" rid="aff4-0883073812450319">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0883073812450319">
<label>1</label>Taoyuan Mental Hospital, Department of Health, Taoyuan, Taiwan</aff>
<aff id="aff2-0883073812450319">
<label>2</label>Department of Public Health and Institute of Public Health, National Yang-Ming University, Taipei, Taiwan</aff>
<aff id="aff3-0883073812450319">
<label>3</label>Taichung Veteran General Hospital, Taichung, Taiwan</aff>
<aff id="aff4-0883073812450319">
<label>4</label>Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan</aff>
<author-notes>
<corresp id="corresp1-0883073812450319">I-Chia Chien, MD, PhD, Taoyuan Mental Hospital, Department of Health, No. 71, Longshow Street, Taoyuan City, Taoyuan County 33058, Taiwan. Email: <email>lewis777@ms26.hinet.net</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>6</issue>
<fpage>706</fpage>
<lpage>712</lpage>
<history>
<date date-type="received">
<day>2</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The authors used a population-based database to investigate antidepressant use among children and adolescents in Taiwan. The National Health Research Institutes provided a database of 1 000 000 random subjects for study. The authors adopted this sample of subjects who were younger than 18 years during 1997 to 2005. Subjects with at least 1 antidepressant prescription were identified. Trends, prevalence, associated factors, and disease patterns of antidepressant use were detected. The 1-year prevalence of pediatric antidepressant use increased from 0.27% in 1997 to 0.47% in 2005. The 1-year prevalence of tricyclic antidepressant, selective serotonin reuptake inhibitor, and other antidepressant use among pediatric population was 0.23%, 0.20%, and 0.08%, respectively, in 2005. The prevalence of pediatric antidepressant use increased from 1997 to 2005. Among pediatric subjects with antidepressant use, selective serotonin reuptake inhibitors, and other antidepressants were used the most for psychiatric disorders, whereas tricyclic antidepressant was used the most for nonpsychiatric disorders.</p>
</abstract>
<kwd-group>
<kwd>trends</kwd>
<kwd>antidepressant</kwd>
<kwd>National Health Insurance</kwd>
<kwd>Taiwan</kwd>
<kwd>psychotropic drug</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The prevalence of psychotropic drug use in pediatric populations has increased worldwide in recent years.<sup><xref ref-type="bibr" rid="bibr1-0883073812450319">1</xref><xref ref-type="bibr" rid="bibr2-0883073812450319"/>–<xref ref-type="bibr" rid="bibr3-0883073812450319">3</xref></sup> Stimulants, anxiolytics, and antidepressants are the 3 leading classes of psychotropic agents that are commonly prescribed for pediatric patients.<sup><xref ref-type="bibr" rid="bibr4-0883073812450319">4</xref></sup> Antidepressant use has increased especially rapidly in recent decades.<sup><xref ref-type="bibr" rid="bibr1-0883073812450319">1</xref>,<xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref>,<xref ref-type="bibr" rid="bibr5-0883073812450319">5</xref>,<xref ref-type="bibr" rid="bibr6-0883073812450319">6</xref></sup> One study estimated the nationwide pediatric antidepressant use in the United States to be 0.3% in 1987 and 1.0% in 1996.<sup><xref ref-type="bibr" rid="bibr7-0883073812450319">7</xref></sup> An increase in pediatric antidepressant use in the United States from 0.9% in 1994 to 2.1% in 2003 was also reported.<sup><xref ref-type="bibr" rid="bibr8-0883073812450319">8</xref></sup> On an international level, the greatest prevalence of antidepressant prescriptions was noted in the United States, followed by Iceland, with prevalence ranging from 0.2% to 0.6% in other European countries.<sup><xref ref-type="bibr" rid="bibr4-0883073812450319">4</xref>,<xref ref-type="bibr" rid="bibr6-0883073812450319">6</xref>,<xref ref-type="bibr" rid="bibr9-0883073812450319">9</xref></sup></p>
<p>Pediatric antidepressant use is affected by several factors. With regard to age, antidepressant use is higher in adolescents and lower in children younger than 6 years. Tricyclic antidepressants are more commonly used in children, and selective serotonin reuptake inhibitors are more commonly used in adolescents.<sup><xref ref-type="bibr" rid="bibr4-0883073812450319">4</xref>,<xref ref-type="bibr" rid="bibr10-0883073812450319">10</xref>,<xref ref-type="bibr" rid="bibr11-0883073812450319">11</xref></sup> In one study, ages of 13 to 18 years, family of lower income, and family receiving public insurance were associated with pediatric antidepressant use, while there were no differences existing with respect to sex, race, or geographic region.<sup><xref ref-type="bibr" rid="bibr10-0883073812450319">10</xref></sup> However, other studies found that female adolescents, white race, residency in the eastern United States, and psychiatric specialist were related to pediatric antidepressant use.<sup><xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref><xref ref-type="bibr" rid="bibr3-0883073812450319"/><xref ref-type="bibr" rid="bibr4-0883073812450319"/>–<xref ref-type="bibr" rid="bibr5-0883073812450319">5</xref>,<xref ref-type="bibr" rid="bibr9-0883073812450319">9</xref></sup></p>
<p>Antidepressants are commonly used in a variety of psychiatric diagnoses, with anxiety-depressive disorders, attention-deficit/hyperactivity disorder, and emotional and behavioral disorders accounting for almost half of the prescriptions.<sup><xref ref-type="bibr" rid="bibr9-0883073812450319">9</xref></sup> Depression and anxiety are more frequent diagnoses among selective serotonin reuptake inhibitor users, while attention-deficit/hyperactivity disorder, conduct disorders, and enuresis are more commonly noted among tricyclic antidepressant users.<sup><xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref>,<xref ref-type="bibr" rid="bibr10-0883073812450319">10</xref></sup> Other disorders, such as eating disorders, phobias, and chronic pain are also noted among pediatric antidepressant users.<sup><xref ref-type="bibr" rid="bibr1-0883073812450319">1</xref></sup> However, only a few antidepressants have been approved for pediatric patients and off-label use is not uncommon. Several studies have reported that off-label use accounts for about three quarters of pediatric antidepressant use.<sup><xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref>,<xref ref-type="bibr" rid="bibr5-0883073812450319">5</xref></sup> Several adverse effects of pediatric antidepressant use have also been reported, especially the Food and Drug Administration black-box warning of suicide, which resulted in an obvious decline in pediatric antidepressant use.<sup><xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref>,<xref ref-type="bibr" rid="bibr4-0883073812450319">4</xref>,<xref ref-type="bibr" rid="bibr6-0883073812450319">6</xref>,<xref ref-type="bibr" rid="bibr12-0883073812450319">12</xref></sup> Studies about the efficacy and safety of pediatric antidepressant use are still limited and the safety issue continues to be heavily debated.<sup><xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref>,<xref ref-type="bibr" rid="bibr3-0883073812450319">3</xref>,<xref ref-type="bibr" rid="bibr6-0883073812450319">6</xref>,<xref ref-type="bibr" rid="bibr9-0883073812450319">9</xref></sup></p>
<p>Taiwan implemented the National Health Insurance program in March 1995. It offers comprehensive, unified, and universal health insurance to all citizens. The National Health Insurance database represents both the contemporary prescription and medical utilization patterns in Taiwan. In this study, we first investigated the trends of antidepressant use within the pediatric population. Second, factors associated with antidepressant use were identified. Third, the proportions of pediatric antidepressant use for psychiatric and nonpsychiatric disorders were examined.</p>
<sec id="section1-0883073812450319" sec-type="methods">
<title>Methods</title>
<p>The National Health Insurance database of medical claims includes outpatient care, inpatient care, dental services, and prescription drugs. The National Health Research Institutes provided a database of 1 000 000 random subjects, about 4.5% of the total population (22.6 million), to perform a related health service study. Longitudinal Health Insurance Database 2005 contains the original claim data of 1 000 000 beneficiaries enrolled in 2005 randomly sampled from the year 2005 Registry for Beneficiaries of the National Health Insurance Research Database, where registration data of everyone who was a beneficiary of the National Health Insurance program during the period of 2005 were drawn for random sampling. All the registration and claim data of these 1 000 000 individuals collected by the National Health Insurance program constitute the Longitudinal Health Insurance Database 2005. There were no statistically significant differences in age, sex, and average insured payroll-related amount between the sample group and all enrollees.</p>
<p>In the investigation of trends in antidepressant use among children and adolescents, we conducted a population-based, random sample study by using data from 1997 to 2005. With regard to the newborn effect, a dynamic cohort was used in the present study. Persons younger than 18 years on July 1 of each year with any record of antidepressant use were included. The initial sample consisted of 264 191 subjects in 1997. In the years 1998 through 2005, 13 299, 12 057, 12 344, 12 613, 10 610, 10 364, 9507, and 9221 newborns entered this cohort, while 18 235, 17 641, 16 679, 16 283, 15 024, 14 255, 13 503, and 13 132 enrollees who turned 18 exited this cohort in the respective years.<sup><xref ref-type="bibr" rid="bibr13-0883073812450319">13</xref></sup> We also identified the prevalence, correlates, and disease patterns of antidepressant use among the study subjects in 2005. The study was approved by the Taoyuan Mental Hospital Institutional Review Board.</p>
<sec id="section2-0883073812450319">
<title>Assessment of Antidepressant Use</title>
<p>In current study, antidepressant drugs were recorded on the basis of the Anatomical Therapeutic Chemical classification system (N06A).<sup><xref ref-type="bibr" rid="bibr14-0883073812450319">14</xref></sup> According to the Anatomical Therapeutic Chemical classification system and previous research,<sup><xref ref-type="bibr" rid="bibr10-0883073812450319">10</xref>,<xref ref-type="bibr" rid="bibr11-0883073812450319">11</xref></sup> we divided antidepressant drugs into 3 categories: the most common conventional antidepressants (tricyclic antidepressant group), the most common new generation antidepressants (selective serotonin reuptake inhibitor group), and other antidepressants. The tricyclic antidepressant group included tricyclic and other norepinephrine-reuptake inhibitors. The selective serotonin reuptake inhibitor group included selective serotonin reuptake inhibitors. The third group included selective serotonin- and norepinephrine-reuptake inhibitors, serotonin modulators, other antidepressants (nutriceutical), and miscellaneous antidepressants in the Anatomical Therapeutic Chemical classification system.<sup><xref ref-type="bibr" rid="bibr11-0883073812450319">11</xref>,<xref ref-type="bibr" rid="bibr14-0883073812450319">14</xref></sup></p>
</sec>
<sec id="section3-0883073812450319">
<title>Measures</title>
<p>We obtained demographic data, including age, sex, geographic distribution, and urbanicity, from the National Health Insurance database. Age was stratified into 3 categories: 0 to 5, 6 to 11, and 12 to 17 years. The urbanicity was divided into 3 categories: urban, suburban, and rural. Factors associated with antidepressant use were examined in this study.</p>
</sec>
<sec id="section4-0883073812450319">
<title>Assessment of Psychiatric Disorder</title>
<p>Subjects with antidepressant use who received at least one service claim in 2005 for either inpatient or outpatient care, with a primary or secondary diagnosis of a psychiatric disorder, were identified. The psychiatric disorders were divided into major psychiatric disorder, minor psychiatric disorder, and mental retardation. Major psychiatric disorders included International Classification of Diseases, Ninth Revision, clinical modification codes 290 through 299; minor psychiatric disorders included codes 300 through 316; and mental retardation included codes 317 through 319.<sup><xref ref-type="bibr" rid="bibr15-0883073812450319">15</xref></sup> We examined the proportion of psychiatric disorders with regard to antidepressant use.</p>
</sec>
<sec id="section5-0883073812450319">
<title>Assessment of Medical Disorder</title>
<p>Subjects with antidepressant use who had at least one service claim in 2005 for either outpatient or inpatient care with the primary diagnosis of a medical disorder were identified. The proportion of medical disorders recorded was examined with regard to antidepressant use.</p>
</sec>
<sec id="section6-0883073812450319">
<title>Statistical Analysis</title>
<p>In our investigation of the trends of pediatric antidepressant use, we examined temporal changes from 1997 to 2005. Time series analysis was performed, and linear models were also used to assess the trends in antidepressant use.</p>
<p>Multiple logistic regression was used to analyze the significant factors associated with tricyclic antidepressant use, selective serotonin reuptake inhibitor use, and other antidepressant use. The regression analysis controlled for the other covariates including age, sex, and urbanicity according to the data from 2005. Data were fit into models using SAS for Window, version 9.1, and the significance level was set at .05.</p>
</sec>
</sec>
<sec id="section7-0883073812450319">
<title>Results</title>
<p><xref ref-type="table" rid="table1-0883073812450319">Table 1</xref> shows the trends in antidepressant use in the pediatric population from 1997 to 2005. The overall 1-year prevalence increased from 0.27% to 0.47% during that time period. No significant difference was noted in age group 0 to 5 years and age group 6 to 11, while the prevalence increased significantly from 0.29% to 0.74% in age group 12 to 17. The increase in antidepressant use was noted in both sexes, from 0.29% to 0.51% in boys and 0.25% to 0.43% in girls. The prevalence of tricyclic antidepressant remained stable, while the prevalence of selective serotonin reuptake inhibitor use increased from 0.05% to 0.20% and the prevalence of other antidepressant use also increased, from 0.02% to 0.08%.</p>
<table-wrap id="table1-0883073812450319" position="float">
<label>Table 1.</label>
<caption>
<p>Prevalence of Antidepressant Use From 1997 to 2005.</p>
</caption>
<graphic alternate-form-of="table1-0883073812450319" xlink:href="10.1177_0883073812450319-table1.tif"/>
<table>
<thead>
<tr>
<th>Year</th>
<th>1997</th>
<th>1998</th>
<th>1999</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>
<italic>t</italic>
<sup>a</sup>
</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects</td>
<td>264 191</td>
<td>259 255</td>
<td>253 671</td>
<td>249 336</td>
<td>245 666</td>
<td>241 252</td>
<td>237 361</td>
<td>233 365</td>
<td>229 454</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Age (y)</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> 0-5</td>
<td>0.18</td>
<td>0.18</td>
<td>0.24</td>
<td>0.24</td>
<td>0.23</td>
<td>0.20</td>
<td>0.19</td>
<td>0.25</td>
<td>0.19</td>
<td>0.47</td>
<td>.650</td>
</tr>
<tr>
<td> 6-11</td>
<td>0.33</td>
<td>0.35</td>
<td>0.41</td>
<td>0.46</td>
<td>0.48</td>
<td>0.47</td>
<td>0.43</td>
<td>0.47</td>
<td>0.41</td>
<td>2.07</td>
<td>.077</td>
</tr>
<tr>
<td> 12-17</td>
<td>0.29</td>
<td>0.33</td>
<td>0.35</td>
<td>0.47</td>
<td>0.49</td>
<td>0.59</td>
<td>0.60</td>
<td>0.72</td>
<td>0.74</td>
<td>17.19</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Sex</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Male</td>
<td>0.29</td>
<td>0.30</td>
<td>0.36</td>
<td>0.39</td>
<td>0.40</td>
<td>0.44</td>
<td>0.41</td>
<td>0.50</td>
<td>0.51</td>
<td>9.66</td>
<td>&lt; .001</td>
</tr>
<tr>
<td> Female</td>
<td>0.25</td>
<td>0.28</td>
<td>0.31</td>
<td>0.39</td>
<td>0.41</td>
<td>0.42</td>
<td>0.41</td>
<td>0.49</td>
<td>0.43</td>
<td>5.96</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Antidepressant</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> TCA</td>
<td>0.21</td>
<td>0.23</td>
<td>0.26</td>
<td>0.30</td>
<td>0.29</td>
<td>0.28</td>
<td>0.25</td>
<td>0.26</td>
<td>0.23</td>
<td>0.53</td>
<td>.610</td>
</tr>
<tr>
<td> SSRI</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
<td>0.07</td>
<td>0.10</td>
<td>0.12</td>
<td>0.14</td>
<td>0.19</td>
<td>0.20</td>
<td>9.76</td>
<td>&lt; .001</td>
</tr>
<tr>
<td> Other</td>
<td>0.02</td>
<td>0.03</td>
<td>0.03</td>
<td>0.04</td>
<td>0.04</td>
<td>0.05</td>
<td>0.06</td>
<td>0.08</td>
<td>0.08</td>
<td>10.39</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Total</td>
<td>0.27</td>
<td>0.29</td>
<td>0.34</td>
<td>0.39</td>
<td>0.40</td>
<td>0.43</td>
<td>0.41</td>
<td>0.49</td>
<td>0.47</td>
<td>8.81</td>
<td>&lt; .001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0883073812450319">
<p>Abbreviations: SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.</p>
</fn>
<fn id="table-fn2-0883073812450319">
<p>
<sup>a</sup> Test for linear trend.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="table2-0883073812450319">Table 2</xref> shows the demographic distribution of the study sample and the prevalence of antidepressant use in the Taiwanese pediatric population in 2005. The 1-year prevalence of tricyclic antidepressant, selective serotonin reuptake inhibitor, and other antidepressant use was 0.23%, 0.20%, and 0.08%, respectively. The overall antidepressant use was higher in 12- to 17-year-olds, and males.</p>
<table-wrap id="table2-0883073812450319" position="float">
<label>Table 2.</label>
<caption>
<p>Demographic Characteristics of Study Sample and Prevalence of Antidepressant Use.</p>
</caption>
<graphic alternate-form-of="table2-0883073812450319" xlink:href="10.1177_0883073812450319-table2.tif"/>
<table>
<thead>
<tr>
<th>Variable</th>
<th>n</th>
<th>Any Antidepressant (%)</th>
<th>TCA (%) </th>
<th>SSRI (%)</th>
<th>Other Antidepressant (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>
</td>
<td> </td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> 0-5</td>
<td>64 659</td>
<td>0.19</td>
<td>0.16</td>
<td>0.01</td>
<td>0.02</td>
</tr>
<tr>
<td> 6-11</td>
<td>81 210</td>
<td>0.41</td>
<td>0.30</td>
<td>0.10</td>
<td>0.02</td>
</tr>
<tr>
<td> 12-17</td>
<td>83 585</td>
<td>0.74</td>
<td>0.21</td>
<td>0.44</td>
<td>0.18</td>
</tr>
<tr>
<td>Sex</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Male</td>
<td>119 752</td>
<td>0.51</td>
<td>0.24</td>
<td>0.21</td>
<td>0.09</td>
</tr>
<tr>
<td> Female</td>
<td>109 702</td>
<td>0.43</td>
<td>0.21</td>
<td>0.19</td>
<td>0.07</td>
</tr>
<tr>
<td>Urbanization</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Urban</td>
<td>133 531</td>
<td>0.49</td>
<td>0.22</td>
<td>0.21</td>
<td>0.09</td>
</tr>
<tr>
<td> Suburban</td>
<td>32 753</td>
<td>0.45</td>
<td>0.27</td>
<td>0.15</td>
<td>0.05</td>
</tr>
<tr>
<td> Rural</td>
<td>63 162</td>
<td>0.43</td>
<td>0.22</td>
<td>0.18</td>
<td>0.07</td>
</tr>
<tr>
<td>Total</td>
<td>229 454</td>
<td>0.47</td>
<td>0.23</td>
<td>0.20</td>
<td>0.08</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0883073812450319">
<p>Abbreviations: SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="table3-0883073812450319">Table 3</xref> shows the logistic regression of factors associated with prevalence of antidepressant use. With regard to age, higher tricyclic antidepressant use was noted in the age 6 to 11 group. Higher selective serotonin reuptake inhibitor use and other antidepressant use were noted in the age 12 to 17 group. There was no significant difference between sexes in the prevalence of 3 kinds of antidepressant use.</p>
<table-wrap id="table3-0883073812450319" position="float">
<label>Table 3.</label>
<caption>
<p>Logistic Regression of Antidepressant Use.</p>
</caption>
<graphic alternate-form-of="table3-0883073812450319" xlink:href="10.1177_0883073812450319-table3.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Variable</th>
<th colspan="2">TCA </th>
<th colspan="2">SSRI</th>
<th colspan="2">Other Antidepressant</th>
</tr>
<tr>
<th>OR</th>
<th>95% CI</th>
<th>OR</th>
<th>95% CI</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> 0-5 </td>
<td>1.00</td>
<td align="center">—</td>
<td>1.00</td>
<td align="center">—</td>
<td>1.00</td>
<td align="center">—</td>
</tr>
<tr>
<td> 6-11</td>
<td>1.94***</td>
<td>1.54–2.45</td>
<td>7.85***</td>
<td>3.80–16.23</td>
<td>1.14</td>
<td>0.57–2.25</td>
</tr>
<tr>
<td> 12-17</td>
<td>1.33*</td>
<td>1.04–1.71</td>
<td>35.22***</td>
<td>17.49–70.92</td>
<td>8.16***</td>
<td>4.72–14.12</td>
</tr>
<tr>
<td>Sex</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Male</td>
<td>1.18</td>
<td>0.99–1.40</td>
<td>1.10</td>
<td>0.92–1.33</td>
<td>1.17</td>
<td>0.87–1.57</td>
</tr>
<tr>
<td> Female</td>
<td>1.00</td>
<td align="center">—</td>
<td>1.00</td>
<td align="center">—</td>
<td>1.00</td>
<td align="center">—</td>
</tr>
<tr>
<td>Urbanization</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Urban</td>
<td>1.02</td>
<td>0.83–1.25</td>
<td>1.15</td>
<td>0.93–1.44</td>
<td>1.28</td>
<td>0.91–1.81</td>
</tr>
<tr>
<td> Suburban</td>
<td>1.24</td>
<td>0.95–1.62</td>
<td>0.83</td>
<td>0.59–1.16</td>
<td>0.65</td>
<td>0.36–1.16</td>
</tr>
<tr>
<td> Rural</td>
<td>1.00</td>
<td align="center">—</td>
<td>1.00</td>
<td align="center">—</td>
<td>1.00</td>
<td align="center">—</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0883073812450319">
<p>Abbreviations: SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.</p>
</fn>
<fn id="table-fn5-0883073812450319">
<p>*<italic>P</italic> &lt; .05. ***<italic>P</italic> &lt; .001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="table4-0883073812450319">Table 4</xref> shows the proportion of psychiatric disorders among subjects according to tricyclic antidepressant, selective serotonin reuptake inhibitor, and other antidepressant use. Psychiatric disorders were commonly found in most selective serotonin reuptake inhibitor and other antidepressant users (98.0% and 81.3%, respectively). Most tricyclic antidepressant users did not have a psychiatric diagnosis, and the proportion of any psychiatric disorder in tricyclic antidepressant users was only 31.1%. The proportion of major psychiatric disorder was 2.5% in tricyclic antidepressant users, 30.4% in selective serotonin reuptake inhibitor users, and 23.6% in other antidepressant users. Among the major psychiatric disorders, the disorders that accounted for higher selective serotonin reuptake inhibitor use were major depressive disorder (16.4%), bipolar affective disorder (4.7%), psychosis with origin specific to childhood (4.2%), and schizophrenic disorders (4.0%). The disorders accounting for higher use of other antidepressants were similar to those with selective serotonin reuptake inhibitor users. The proportion of major psychiatric disorders in tricyclic antidepressant users was relatively low.</p>
<table-wrap id="table4-0883073812450319" position="float">
<label>Table 4.</label>
<caption>
<p>Proportion of Psychiatric Disorder Among Subjects With Antidepressant Use.</p>
</caption>
<graphic alternate-form-of="table4-0883073812450319" xlink:href="10.1177_0883073812450319-table4.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Psychiatric disorder (ICD-9-CM code)</th>
<th colspan="2">TCA (n = 512)</th>
<th colspan="2">SSRI (n = 451)</th>
<th colspan="2">Other Antidepressant (n = 182)</th>
</tr>
<tr>
<td align="center">n</td>
<td align="center">%</td>
<td align="center">n</td>
<td align="center">%</td>
<td align="center">n</td>
<td align="center">%</td>
</tr>
</thead>
<tbody>
<tr>
<td>Without psychiatric disorder</td>
<td>359</td>
<td>68.9</td>
<td>9</td>
<td>2.0</td>
<td>34</td>
<td>18.7</td>
</tr>
<tr>
<td>Any psychiatric disorder</td>
<td>162</td>
<td>31.1</td>
<td>442</td>
<td>98.0</td>
<td>148</td>
<td>81.3</td>
</tr>
<tr>
<td>Any major psychiatric disorder</td>
<td>13</td>
<td>2.5</td>
<td>137</td>
<td>30.4</td>
<td>43</td>
<td>23.6</td>
</tr>
<tr>
<td> Schizophrenic disorders (295)</td>
<td>1</td>
<td>0.2</td>
<td>18</td>
<td>4.0</td>
<td>6</td>
<td>3.3</td>
</tr>
<tr>
<td> Affective psychoses (296)</td>
<td>7</td>
<td>1.3</td>
<td>96</td>
<td>21.3</td>
<td>31</td>
<td>17.0</td>
</tr>
<tr>
<td> Major depressive disorder (296.2, 296.3)</td>
<td>6</td>
<td>1.2</td>
<td>74</td>
<td>16.4</td>
<td>27</td>
<td>14.8</td>
</tr>
<tr>
<td> Bipolar affective disorder (296)</td>
<td>1</td>
<td>0.2</td>
<td>21</td>
<td>4.7</td>
<td>4</td>
<td>2.2</td>
</tr>
<tr>
<td> Psychoses with origin specific to childhood (299)</td>
<td>4</td>
<td>0.8</td>
<td>19</td>
<td>4.2</td>
<td>4</td>
<td>2.2</td>
</tr>
<tr>
<td>Any minor psychiatric disorder</td>
<td>153</td>
<td>29.4</td>
<td>379</td>
<td>84.0</td>
<td>125</td>
<td>68.7</td>
</tr>
<tr>
<td> Neurotic disorders (300)</td>
<td>31</td>
<td>6.0</td>
<td>219</td>
<td>48.6</td>
<td>74</td>
<td>40.7</td>
</tr>
<tr>
<td> Anxiety state (300.0)</td>
<td>18</td>
<td>3.5</td>
<td>55</td>
<td>12.2</td>
<td>30</td>
<td>16.5</td>
</tr>
<tr>
<td> Anxiety disorders (300.0 except 300.01)</td>
<td>17</td>
<td>3.3</td>
<td>51</td>
<td>11.3</td>
<td>29</td>
<td>15.9</td>
</tr>
<tr>
<td> Phobic state (300.2)</td>
<td>0</td>
<td>0.0</td>
<td>21</td>
<td>4.7</td>
<td>6</td>
<td>3.3</td>
</tr>
<tr>
<td> Obsessive-compulsive disorders (300.3)</td>
<td>0</td>
<td>0.0</td>
<td>44</td>
<td>9.8</td>
<td>5</td>
<td>2.7</td>
</tr>
<tr>
<td> Neurotic depression (300.4)</td>
<td>9</td>
<td>1.7</td>
<td>121</td>
<td>26.8</td>
<td>39</td>
<td>21.4</td>
</tr>
<tr>
<td> Special symptoms or syndromes not elsewhere classified (307)</td>
<td>93</td>
<td>17.9</td>
<td>29</td>
<td>6.4</td>
<td>13</td>
<td>7.1</td>
</tr>
<tr>
<td> Specific disorders of sleep of nonorganic origin (307.4)</td>
<td>6</td>
<td>1.2</td>
<td>12</td>
<td>2.7</td>
<td>7</td>
<td>3.8</td>
</tr>
<tr>
<td> Enuresis (307.6)</td>
<td>75</td>
<td>14.4</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td> Adjustment reaction (309)</td>
<td>7</td>
<td>1.3</td>
<td>68</td>
<td>15.1</td>
<td>22</td>
<td>12.1</td>
</tr>
<tr>
<td> Depressive disorder, not elsewhere classified (311)</td>
<td>7</td>
<td>1.3</td>
<td>42</td>
<td>9.3</td>
<td>15</td>
<td>8.2</td>
</tr>
<tr>
<td> Disturbance of conduct not elsewhere classified (312)</td>
<td>3</td>
<td>0.6</td>
<td>12</td>
<td>2.7</td>
<td>6</td>
<td>3.3</td>
</tr>
<tr>
<td> Disturbance of emotions specific to childhood and adolescence (313)</td>
<td>10</td>
<td>1.9</td>
<td>67</td>
<td>14.9</td>
<td>11</td>
<td>6.0</td>
</tr>
<tr>
<td> Hyperkinetic syndrome of childhood (314)</td>
<td>24</td>
<td>4.6</td>
<td>68</td>
<td>15.1</td>
<td>26</td>
<td>14.3</td>
</tr>
<tr>
<td>Any mental retardation</td>
<td>6</td>
<td>1.2</td>
<td>22</td>
<td>4.9</td>
<td>4</td>
<td>2.2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0883073812450319">
<p>Abbreviations: ICD-9-CM, International Classification of Diseases, Ninth Revision, clinical modification; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Among the minor psychiatric disorders, those associated with higher tricyclic antidepressant use were special symptoms or syndromes not elsewhere classified (17.9%; especially including enuresis 14.4%), and hyperkinetic syndrome of childhood (4.6%). Those associated with the higher use of selective serotonin reuptake inhibitors were neurotic depression (26.8%), adjustment reaction (15.1%), and attention-deficit/hyperactivity disorder (15.1%). The minor psychiatric disorders associated with higher use of other antidepressants were similar to those of the selective serotonin reuptake inhibitors.</p>
<p>Finally, with respect to the proportion of medical disorder, higher tricyclic antidepressant use was for symptoms, signs, and ill-defined conditions (42.6%), diseases of the genitourinary system (25.3%), and diseases of the respiratory system (18.1%).</p>
</sec>
<sec id="section8-0883073812450319">
<title>Discussion</title>
<p>This report is the first study to examine antidepressant use within a pediatric population in Taiwan. In this study, the overall prevalence of antidepressant use increased from 0.27% to 0.47% from 1997 to 2005, which was similar to findings in other countries.<sup><xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref>,<xref ref-type="bibr" rid="bibr10-0883073812450319">10</xref>,<xref ref-type="bibr" rid="bibr11-0883073812450319">11</xref></sup> In addition, the prevalence of selective serotonin reuptake inhibitor use increased from 0.05% to 0.20%, and the prevalence of use of other antidepressants also increased, from 0.02% to 0.08%, while the prevalence of tricyclic antidepressant use remained stable. In one study performed in Canada, the number of antidepressant users increased from 1997 to 2005 but decreased thereafter.<sup><xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref></sup> A medical expenditure–based national estimate in the United States reported the increase of antidepressant use from 1.3% in 1997 to 1.8% in 2002.<sup><xref ref-type="bibr" rid="bibr10-0883073812450319">10</xref></sup> Scientific publications about the efficacy of antidepressants in treating pediatric depression may influence clinical practice and may have promoted the increase. Fewer side effects of new generation antidepressants has also increased the utilization. On the other hand, the black-box warning on the risk of increased suicide ideation may be related to the attenuation of the trends in some reports.<sup><xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref>,<xref ref-type="bibr" rid="bibr12-0883073812450319">12</xref>,<xref ref-type="bibr" rid="bibr16-0883073812450319">16</xref></sup> In this study, the estimated 1-year prevalence of antidepressant use in Taiwan was 0.47%, which was lower than in the United States (2.37%) but close to use in European countries.<sup><xref ref-type="bibr" rid="bibr3-0883073812450319">3</xref>,<xref ref-type="bibr" rid="bibr6-0883073812450319">6</xref>,<xref ref-type="bibr" rid="bibr10-0883073812450319">10</xref>,<xref ref-type="bibr" rid="bibr11-0883073812450319">11</xref>,<xref ref-type="bibr" rid="bibr17-0883073812450319">17</xref><xref ref-type="bibr" rid="bibr18-0883073812450319"/>–<xref ref-type="bibr" rid="bibr19-0883073812450319">19</xref></sup></p>
<p>The current study also revealed that the prevalence of antidepressant use increased with age. The increasing trend from 1997 to 2005 was mainly found in the 12-17 age group. This result is consistent with studies in Western countries.<sup><xref ref-type="bibr" rid="bibr3-0883073812450319">3</xref>,<xref ref-type="bibr" rid="bibr4-0883073812450319">4</xref>,<xref ref-type="bibr" rid="bibr6-0883073812450319">6</xref>,<xref ref-type="bibr" rid="bibr10-0883073812450319">10</xref>,<xref ref-type="bibr" rid="bibr11-0883073812450319">11</xref></sup> More adolescents with depression, anxiety, and related problems may have been brought for psychiatric treatment, thus more antidepressants were prescribed. Taking different kinds of antidepressants into account, tricyclic antidepressant was the most frequently dispensed product among children, while selective serotonin reuptake inhibitors and other antidepressants were more commonly used among adolescents.<sup><xref ref-type="bibr" rid="bibr3-0883073812450319">3</xref>,<xref ref-type="bibr" rid="bibr4-0883073812450319">4</xref>,<xref ref-type="bibr" rid="bibr6-0883073812450319">6</xref>,<xref ref-type="bibr" rid="bibr10-0883073812450319">10</xref>,<xref ref-type="bibr" rid="bibr11-0883073812450319">11</xref></sup></p>
<p>Boys had a higher rate of antidepressant use than did girls (0.51% vs. 0.43%, <italic>P</italic> &lt; .05) in the current study. A Canadian study had similar results, but the pattern was limited to children younger than 10 years.<sup><xref ref-type="bibr" rid="bibr2-0883073812450319">2</xref></sup> However, one Dutch study reported that physicians prescribed antidepressants to girls more often than boys.<sup><xref ref-type="bibr" rid="bibr4-0883073812450319">4</xref></sup> The prevalence of psychiatric disorders varies between the sexes at different ages, and the disease pattern may also have influence on antidepressant use.</p>
<p>In the current study, most tricyclic antidepressant users did not have any psychiatric diagnosis, while most selective serotonin reuptake inhibitor and other antidepressant users had at least one psychiatric disorder. Affective psychosis, especially major depressive disorder, was the most common major psychiatric disorder of individuals using selective serotonin reuptake inhibitors and other antidepressants. Major depressive disorder in child and adolescent populations is a serious public health problem. When undertreated or untreated, depressed youth may have poor long-term outcomes.<sup><xref ref-type="bibr" rid="bibr20-0883073812450319">20</xref></sup> Thus, early identification and adequate treatment is of great importance. Stigma associated with use of psychotropic agents and resistance to using them were significant barriers to recognizing and treating psychiatric disorders in Taiwan.<sup><xref ref-type="bibr" rid="bibr21-0883073812450319">21</xref></sup> The previous study revealed that prevalence rate of major depressive disorder in seventh, eighth, and ninth grade students were 0.5%, 2.5%, and 4.4%, respectively.<sup><xref ref-type="bibr" rid="bibr21-0883073812450319">21</xref></sup> Our results imply that lower than 30% pediatric patients with major depressive disorder used selective serotonin reuptake inhibitors and other antidepressants, while some children with major depressive disorder were treated with nonmedication therapy in Taiwan.</p>
<p>A significant incidence of schizophrenic disorders and autism spectrum disorders were also noted for selective serotonin reuptake inhibitor and other antidepressant users in our study. With schizophrenia, a younger age of onset is related to more negative and depressive symptoms.<sup><xref ref-type="bibr" rid="bibr22-0883073812450319">22</xref></sup> Clinical trials have reported improvement of negative symptoms with the addition of selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, trazodone, and mirtazapine to antipsychotics.<sup><xref ref-type="bibr" rid="bibr23-0883073812450319">23</xref><xref ref-type="bibr" rid="bibr24-0883073812450319"/><xref ref-type="bibr" rid="bibr25-0883073812450319"/>–<xref ref-type="bibr" rid="bibr26-0883073812450319">26</xref></sup> With regard to autism, a study reported antidepressants to be one of the leading 3 psychotropic drugs among children with autism and the use may be related to aging, more psychiatric comorbidity, and intellectual disability.<sup><xref ref-type="bibr" rid="bibr27-0883073812450319">27</xref></sup> Selective serotonin reuptake inhibitors and venlafaxine have been reported to be effective in the attenuation of rituals, stereotypical and repetitive behaviors, overadherence to routines, restricted interest, social deficits, inattention, and hyperactivity in autism and other autistic spectrum disorders.<sup><xref ref-type="bibr" rid="bibr27-0883073812450319">27</xref>,<xref ref-type="bibr" rid="bibr28-0883073812450319">28</xref></sup></p>
<p>In contrast to tricyclic antidepressant, selective serotonin reuptake inhibitors and other antidepressants are commonly used for disorders such as anxiety, minor depressive disorders, adjustment reactions, and other emotional disorders. Depression and anxiety were also the most common diagnoses among selective serotonin reuptake inhibitor users in other studies.<sup><xref ref-type="bibr" rid="bibr29-0883073812450319">29</xref>,<xref ref-type="bibr" rid="bibr30-0883073812450319">30</xref></sup> In our study, antidepressant use was common for managing depression, including major depressive disorder and other minor depressive disorders.</p>
<p>In addition, anxiety disorders such as generalized anxiety disorder, obsessive compulsive disorder, and phobic state also account for a large proportion (about 30%) of selective serotonin reuptake inhibitor and other antidepressant use. Like youth with pediatric depression, those with anxiety are at increased risk of additional psychopathology and poor outcome.<sup><xref ref-type="bibr" rid="bibr31-0883073812450319">31</xref>,<xref ref-type="bibr" rid="bibr32-0883073812450319">32</xref></sup> For children and adolescents with mild anxiety disorder, substantial evidence supports the efficacy of cognitive-behavioral therapy.<sup><xref ref-type="bibr" rid="bibr33-0883073812450319">33</xref></sup> Medication is recommended for management of children and adolescents with moderate or severe symptoms, and selective serotonin reuptake inhibitors have emerged as the medications of choice.<sup><xref ref-type="bibr" rid="bibr33-0883073812450319">33</xref><xref ref-type="bibr" rid="bibr34-0883073812450319"/>–<xref ref-type="bibr" rid="bibr35-0883073812450319">35</xref></sup> However, there are no established selective serotonin reuptake inhibitor dosing guidelines for the pediatric population.<sup><xref ref-type="bibr" rid="bibr36-0883073812450319">36</xref></sup></p>
<p>Our report also indicates that antidepressants, especially selective serotonin reuptake inhibitors and other antidepressants, are also commonly used among patients with a diagnosis of attention-deficit/hyperactivity disorder. A few studies have emphasized the rate of depression as a comorbidity in attention-deficit/hyperactivity disorder.<sup><xref ref-type="bibr" rid="bibr37-0883073812450319">37</xref></sup> The cumulative effects of attention-deficit/hyperactivity disorder–related impairment and the negative environment resulting from attention-deficit/hyperactivity disorder may lead to depression several years after the onset of attention-deficit/hyperactivity disorder.<sup><xref ref-type="bibr" rid="bibr38-0883073812450319">38</xref>,<xref ref-type="bibr" rid="bibr39-0883073812450319">39</xref></sup> The co-occurrence of depression and attention-deficit/hyperactivity disorder may result in a greater level of impairment.<sup><xref ref-type="bibr" rid="bibr40-0883073812450319">40</xref></sup></p>
<p>Finally, our data reported several medical diagnoses among tricyclic antidepressant users. The medical utilization of tricyclic antidepressant focused mostly on the management of genitourinary tract problems. Patients with diseases of the respiratory system or the skin and subcutaneous tissue were also noted. Although tricyclic antidepressants have been suggested to prevent postherpetic neuralgia and the attenuation of urticaria,<sup><xref ref-type="bibr" rid="bibr41-0883073812450319">41</xref>,<xref ref-type="bibr" rid="bibr42-0883073812450319">42</xref></sup> further investigation to evaluate prescription behavior will be needed.</p>
<p>Although a broad pediatric application of antidepressants was revealed in our results and in other studies, only a limited number of antidepressants have been approved by the Food and Drug Administration in the United States, and off-label use is not uncommon.<sup><xref ref-type="bibr" rid="bibr4-0883073812450319">4</xref>,<xref ref-type="bibr" rid="bibr5-0883073812450319">5</xref></sup> The vulnerability of children and adolescents to adverse effects of antidepressant, the black-box warning of suicide, and the extent of off-label use should also be taken into account in clinical practice. In Taiwan, data regarding the extent of off-label use and the positive or negative impact on pediatric population are also lacking. Further investigation will be needed.</p>
<p>Several limitations existed in our study. First, the disease pattern was estimated through the registration of diagnostic code in the National Health Insurance system. Second, the prescription patterns of antidepressants such as dosage, duration, and the physician subspecialist were not investigated. Third, although we tried to make comparisons between Taiwan and other countries, differences in study designs and statistical methods made it difficult. Fourth, other limitations are the cross-sectional nature of the study, the absence of a comparison group (eg, those with psychiatric diagnoses listed who did not use antidepressants), and the fact that nonmedication therapies were not investigated or reported.</p>
</sec>
<sec id="section9-0883073812450319">
<title>Conclusion</title>
<p>The prevalence of selective serotonin reuptake inhibitor and other antidepressant use increased from 1997 to 2005 in the pediatric population in Taiwan. Among pediatric subjects with antidepressant use, selective serotonin reuptake inhibitor and other antidepressants were most used for psychiatric disorders, while tricyclic antidepressants were most used for nonpsychiatric disorders. Further investigation of indication, dosage, frequency, duration, adverse effects, and off-label uses of pediatric antidepressants is warranted.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank the National Health Research Institute for supplying data.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn4-0883073812450319"><label>Author Contributions</label>
<p>ICC and YCH designed the study and wrote the manuscript. HKLT designed the study and organized the process of the study. CHL analyzed the data. SWC, PC, and YJC were involved at the conception level of the project. All authors contributed to and have approved the final article.</p></fn>
<fn fn-type="conflict" id="fn1-0883073812450319"><label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0883073812450319"><label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study received funding support from Department of Health (Grant 100-19) in Taiwan. </p>
</fn>
<fn fn-type="other" id="fn3-0883073812450319">
<label>Ethical Approval</label>
<p>This study was approved by the Taoyuan Mental Hospital Institutional Review Board.</p>
</fn></fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812450319">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cherma</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Ahlner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bengtsson</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gustafsson</surname>
<given-names>PA</given-names>
</name>
</person-group>. <article-title>Antidepressant drugs in children and adolescents: analytical and demographic data in a naturalistic, clinical study</article-title>. <source>J Clin Psychopharmacol</source>. <year>2011</year>;<volume>31</volume>(<issue>1</issue>):<fpage>98</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812450319">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tournier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Greenfield</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Galbaud du Fort</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Patterns of antidepressant use in Quebec children and adolescents: trends and predictors</article-title>. <source>Psychiatry Res</source>. <year>2010</year>;<volume>179</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812450319">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoëga</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Baldursson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hrafnkelsson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Almarsdóttir</surname>
<given-names>AB</given-names>
</name>
</person-group>. <article-title>Psychotropic drug use among Icelandic children: a nationwide population based study</article-title>. <source>J Child Adolesc Psychopharmacol</source>. <year>2009</year>;<volume>19</volume>(<issue>6</issue>):<fpage>757</fpage>–<lpage>764</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812450319">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volkers</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Heerdink</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>van Dijk</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005)</article-title>. <source>Pharmacoepidemiol Drug Safety</source>. <year>2007</year>;<volume>16</volume>(<issue>9</issue>):<fpage>1054</fpage>–<lpage>1062</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812450319">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Teschemaker</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Johann-Liang</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Off-label prescribing patterns of antidepressants in children and adolescents</article-title>. <source>Pharmacoepidemiol Drug Safety</source>. <year>2012</year>;<volume>21</volume>(<issue>2</issue>):<fpage>137</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812450319">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zito</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Tobi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>de Jong-van den Berg</surname>
<given-names>LT</given-names>
</name>
<etal/>
</person-group>. <article-title>Antidepressant prevalence for youths: a multi-national comparison</article-title>. <source>Pharmacoepidemiol Drug Safety</source>. <year>2006</year>;<volume>15</volume>(<issue>11</issue>):<fpage>793</fpage>–<lpage>798</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812450319">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olfson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Weissman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>PS</given-names>
</name>
</person-group>. <article-title>National trends in the use of psychotropic medications by children</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source>. <year>2002</year>;<volume>41</volume>(<issue>5</issue>):<fpage>514</fpage>–<lpage>521</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812450319">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunkeler</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Fireman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Trends in the use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994-2003</article-title>. <source>J Child Adolesc Psychopharmacol</source>. <year>2005</year>(<issue>1</issue>);<volume>15</volume>;<fpage>26</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812450319">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koelch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prestel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns</article-title>. <source>J Child Adolesc Psychopharmacol</source>. <year>2009</year>;<volume>19</volume>(<issue>6</issue>):<fpage>765</fpage>–<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812450319">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vitiello</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zuvekas</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Norquist</surname>
<given-names>GS</given-names>
</name>
</person-group>. <article-title>National estimates of antidepressant medication use among U.S. children, 1997-2002</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source>. <year>2006</year>;<volume>45</volume>(<issue>3</issue>):<fpage>271</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr11-0883073812450319">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delate</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gelenberg</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Motheral</surname>
<given-names>BR</given-names>
</name>
</person-group>. <article-title>Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002</article-title>. <source>Psychiatr Serv</source>. <year>2004</year>;<volume>55</volume>(<issue>4</issue>):<fpage>387</fpage>–<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812450319">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurian</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Arbogast</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>DC</given-names>
</name>
</person-group>. <article-title>Effect of regulatory warning on antidepressant prescribing for children and adolescents</article-title>. <source>Arch Pediatr Adolesc Med</source>. <year>2007</year>;<volume>161</volume>(<issue>7</issue>):<fpage>690</fpage>–<lpage>696</lpage>.</citation>
</ref>
<ref id="bibr13-0883073812450319">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chien</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Prevalence and incidence of autism spectrum disorders among national health insurance enrollees in Taiwan from 1996 to 2005</article-title>. <source>J Child Neurol</source>. <year>2011</year>;<volume>26</volume>(<issue>7</issue>):<fpage>830</fpage>–<lpage>834</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812450319">
<label>14</label>
<citation citation-type="book">
<collab collab-type="author">WHO Collaborating Centre for Drug Statistics Methodology</collab>. <source>Guidelines for ATC Classification and DDD Assignment</source>. <publisher-loc>Oslo, Norway</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2005</year>.</citation>
</ref>
<ref id="bibr15-0883073812450319">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chien</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Bih</surname>
<given-names>SH</given-names>
</name>
</person-group>. <article-title>Prevalence of psychiatric disorders among National Health Insurance enrollees in Taiwan</article-title>. <source>Psychiatr Serv</source>. <year>2004</year>;<volume>55</volume>(<issue>6</issue>):<fpage>691</fpage>–<lpage>697</lpage>.</citation>
</ref>
<ref id="bibr16-0883073812450319">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rais</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kumari</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Decreased use of antidepressants in youth after US food and drug administration black box warning</article-title>. <source>Psychiatry</source>. <year>2009</year>;<volume>6</volume>(<issue>10</issue>):<fpage>30</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812450319">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clavenna</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Derosa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bonati</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Use of psychotropic medications in Italian children and adolescents</article-title>. <source>Eur J Pediatr</source>. <year>2007</year>;<volume>166</volume>(<issue>4</issue>):<fpage>339</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr18-0883073812450319">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fegert</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kolch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zito</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Glaeske</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Antidepressant use in children and adolescents in Germany</article-title>. <source>J Child Adolesc Psychopharmocol</source>. <year>2006</year>;<volume>16</volume>(<issue>1-2</issue>):<fpage>197</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr19-0883073812450319">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sevilla-Dedieu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kovess-Masféty</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Psychotropic medication use in children and adolescents: a study from France</article-title>. <source>J Child Adolesc Psychopharmacol</source>. <year>2008</year>;<volume>18</volume>(<issue>3</issue>):<fpage>281</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr20-0883073812450319">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stein</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Zitner</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>PS</given-names>
</name>
</person-group>. <article-title>Interventions for adolescent depression in primary care</article-title>. <source>Pediatrics</source>. <year>2006</year>;<volume>118</volume>(<issue>2</issue>):<fpage>669</fpage>–<lpage>682</lpage>.</citation>
</ref>
<ref id="bibr21-0883073812450319">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gau</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>AT</given-names>
</name>
</person-group>. <article-title>A 3-year panel study of mental disorders among adolescents in Taiwan</article-title>. <source>Am J Psychiatry</source>. <year>2005</year>;<volume>162</volume>(<issue>7</issue>):<fpage>1344</fpage>–<lpage>1350</lpage>.</citation>
</ref>
<ref id="bibr22-0883073812450319">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellino</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rocca</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Patria</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients</article-title>. <source>J Clin Psychiatry</source>. <year>2004</year>;<volume>65</volume>(<issue>7</issue>):<fpage>908</fpage>–<lpage>914</lpage>.</citation>
</ref>
<ref id="bibr23-0883073812450319">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bucci</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>The negative symptoms of schizophrenia and the monoamine oxidase inhibitors</article-title>. <source>Psychopharmacology</source>. <year>1987</year>;<volume>91</volume>(<issue>1</issue>):<fpage>104</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr24-0883073812450319">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Decina</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mukherjee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bocola</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Saraceni</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hosp Community</article-title> <source>Psychiatry</source>. <year>1994</year>;<volume>45</volume>(<issue>12</issue>):<fpage>1220</fpage>–<lpage>1223</lpage>.</citation>
</ref>
<ref id="bibr25-0883073812450319">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silver</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Fluvoxamine as an adjunctive agent in schizophrenia</article-title>. <source>CNS Drug Rev</source>. <year>2001</year>;<volume>7</volume>(<issue>3</issue>):<fpage>283</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr26-0883073812450319">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoccali</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Muscatello</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Cedro</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study</article-title>. <source>Int Clin Psychopharmacol</source>. <year>2004</year>;<volume>19</volume>(<issue>2</issue>):<fpage>71</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr27-0883073812450319">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Findling</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders</article-title>. <source>J Clin Psychiatry</source>. <year>2005</year>;<volume>66</volume>
<issue>(suppl. 10)</issue>:<fpage>26</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr28-0883073812450319">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollander</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cartwright</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reichman</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Venlafaxine in children, adolescents and young adults with autism spectrum disorders: an open retrospective clinical report</article-title>. <source>J Child Neurol</source>. <year>2000</year>;<volume>15</volume>(<issue>2</issue>):<fpage>132</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr29-0883073812450319">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>IC</given-names>
</name>
</person-group>. <article-title>A drug utilization study of antidepressants in children and adolescents using the General Practice Research Database</article-title>. <source>Arch Dis Child</source>. <year>2004</year>;<volume>89</volume>(<issue>12</issue>):<fpage>1098</fpage>–<lpage>1102</lpage>.</citation>
</ref>
<ref id="bibr30-0883073812450319">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zito</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Safer</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>DosReis</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Rising prevalence of antidepressants among US youths</article-title>. <source>Pediatrics</source>. <year>2002</year>;<volume>109</volume>(<issue>5</issue>):<fpage>721</fpage>–<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr31-0883073812450319">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grover</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Ginsburg</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Ialongo</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Psychosocial outcomes of anxious first graders: a seven-year follow-up</article-title>. <source>Depress Anxiety</source>. <year>2007</year>;<volume>24</volume>(<issue>6</issue>):<fpage>410</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr32-0883073812450319">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messer</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Beidel</surname>
<given-names>DC</given-names>
</name>
</person-group>. <article-title>Psychosocial correlates of childhood anxiety disorders</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source>. <year>1994</year>;<volume>33</volume>:<fpage>975</fpage>–<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr33-0883073812450319">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Compton</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>March</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Brent</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Albano</surname>
<given-names>AM</given-names>
</name>
</person-group>. <article-title>Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based review</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source>. <year>2004</year>;<volume>43</volume>(<issue>8</issue>):<fpage>930</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr34-0883073812450319">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beidel</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Sallee</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Ammerman</surname>
<given-names>RT</given-names>
</name>
</person-group>. <article-title>SET-C versus fluoxetine in the treatment of childhood social phobia</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source>. <year>2007</year>;<volume>46</volume>(<issue>12</issue>):<fpage>1622</fpage>–<lpage>1632</lpage>.</citation>
</ref>
<ref id="bibr35-0883073812450319">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seidel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Walkup</surname>
<given-names>JT</given-names>
</name>
</person-group>. <article-title>Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders</article-title>. <source>J Child Adolesc Psychopharmacol</source>. <year>2006</year>;<volume>16</volume>(<issue>1-2</issue>):<fpage>171</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr36-0883073812450319">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walkup</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Labellarte</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Complication of SSRI treatment</article-title>. <source>J Child Adolesc Psychopharmacol</source>. <year>2001</year>;<volume>11</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr37-0883073812450319">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angold</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Costello</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Erkanli</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Comorbidity</article-title>. <source>J Child Psychol Psychiatry</source>. <year>1999</year>;<volume>40</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr38-0883073812450319">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blackman</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Ostrander</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>KC</given-names>
</name>
</person-group>. <article-title>Children with ADHD and depression: a multisource, multimethod assessment of clinical, social, and academic functioning</article-title>. <source>J Atten Disord</source>. <year>2005</year>;<volume>8</volume>(<issue>4</issue>):<fpage>195</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr39-0883073812450319">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ostrander</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>KC</given-names>
</name>
</person-group>. <article-title>Potential cognitive, parenting, and developmental mediators of the relationship between ADHD and depression</article-title>. <source>J Consult Clin Psychol</source>. <year>2006</year>;<volume>74</volume>(<issue>1</issue>):<fpage>89</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr40-0883073812450319">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohde</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lewinsohn</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Seeley</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults</article-title>. <source>J Abnorm Psychol</source>. <year>1991</year>;<volume>100</volume>(<issue>2</issue>):<fpage>214</fpage>–<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr41-0883073812450319">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Guptat</surname>
<given-names>AK</given-names>
</name>
</person-group>. <article-title>The use of antidepressant drugs in dermatology</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2001</year>;<volume>15</volume>(<issue>6</issue>):<fpage>512</fpage>–<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr42-0883073812450319">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levin</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Gershon</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Dworkin</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Brisson</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Prevention strategies for herpes zoster and post-herpetic neuralgia</article-title>. <source>J Clin Virol</source>. <year>2010</year>;<volume>48</volume>
<issue>(suppl. 1)</issue>:<fpage>S14</fpage>–<lpage>S19</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>